SCHEMBL1077147

SCHEMBL1077147

CCC(O)(CC)C(O)(CC)CO

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.33
TSHR P16473 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17468053 0.93 ALDH1A1 (0.33) ALDH1A1TSHRSMN1; SMN2
SCHEMBL1033095 0.84 TSHR (0.39) ALDH1A1TSHR
SCHEMBL27796273 0.83 ALDH1A1 (0.31) ALDH1A1TSHR
SCHEMBL14350954 0.80 TSHR (0.33) ALDH1A1TSHR
SCHEMBL1093563 0.78 CES1 (0.31)
SCHEMBL17464938 0.78 TSHR (0.32) TSHR
SCHEMBL8111102 0.76 ALDH1A1 (0.31) ALDH1A1TSHR
SCHEMBL4712784 0.76 FDPS (0.43) ALDH1A1TSHR
SCHEMBL8495787 0.76 TSHR (0.30) TSHR
SCHEMBL2303938 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 421 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122075427-A Burisperidone tablet and preparation method thereof 2026-05-26 CN claimed
CN-122070903-A Liquid slow-release preparation 上海建毅腾创生物医药科技有限公司 2026-05-22 CN claimed
CN-119971120-A Seamable film with adhesion capability and preparation method thereof 鹏拓生物科技(杭州)有限公司 2025-05-13 CN claimed
CN-119770445-A Preparation method of dapagliflozin tablet 湖北广济药业股份有限公司 2025-04-08 CN claimed
CN-119679745-A One-step formed enteric gelatin hollow capsule and preparation method thereof 江苏力凡胶囊有限公司 2025-03-25 CN claimed
CN-119607232-A Low-adhesion sterilized gauze preparation device and preparation method 江苏信立康医疗科技有限公司 2025-03-14 CN claimed
CN-119285855-A Copolymer electrolyte based on N-vinyl pyrrolidone and preparation method thereof 上海宇昂水性新材料科技股份有限公司 2025-01-10 CN claimed
CN-119215020-A The present vitamin mod oral soluble film composition, its preparation method and its application in medicine 上海泽德曼医药科技有限公司 2024-12-31 CN claimed
CN-116251075-B Lansoprazole enteric capsule and preparation method thereof 江苏慧聚药业股份有限公司 2024-11-29 CN claimed
CN-113842376-B Pharmaceutical composition containing risperidone, oral film and preparation method 齐鲁制药有限公司 2024-10-11 CN claimed
WO-2004011054-A2 INJECTABLE MULTIMODAL POLYMER DEPOT COMPOSITIONS AND USES THEREOF ALZA CORPORATION (US) 2004-02-05 WO claimed
US-20040022859-A1 Injectable multimodal polymer depot compositions and uses thereof DURECT CORPORATION 2004-02-05 US claimed
US-6673767-B1 DRUG DELIVERY USING TIME-RELEASE AGENTS COMPRISINGS POLYLACTIC ACID, PLASTICIZER SOLVENTS SELECTED FROM BENZYL OR ETHYL BENZOATE AND CDNA, DNA, PROTEINS, PEPTIDES AND/OR ANTICARCINOGENIC AGENTS ALZA CORPORATION 2004-01-06 US claimed
US-20030211974-A1 Gel composition and methods DURECT CORPORATION 2003-11-13 US claimed
US-20030044467-A1 Gel composition and methods DURECT CORPORATION 2003-03-06 US claimed
US-6468961-B1 IMPLANTABLE COMPOSITION FOR SUSTAINED DELIVERY OF BENEFICIAL AGENT COMPRISING POLYLACTIDE POLYMER, AMOUNT OF SOLVENT COMPRISING LOWER ALKYL OR ARALKYL ESTER OF BENZOIC ACID EFFECTIVE TO FORM VISCOUS GEL, BENEFICIAL AGENT ALZA CORPORATION 2002-10-22 US claimed
US-6130200-A Gel composition and methods ALZA CORPORATION (US) 2000-10-10 US claimed
EP-0959873-A2 GEL COMPOSITION AND METHODS ALZA CORPORATION (US) 1999-12-01 EP claimed
WO-1998027963-A2 GEL COMPOSITION AND METHODS ALZA CORPORATION (US) 1998-07-02 WO claimed
US-H1565-H Superabsorbent, continuous filament web DEUTSCHE BANK AG, NEW YORK BRANCH 1996-07-02 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040022859-A1 Injectable multimodal polymer depot compositions and uses thereof CD44, PLOD3, PUF60 ALDH1A1 3842/4885TSHR 1605/4885SMN1; SMN2 3165/4885
US-20030211974-A1 Gel composition and methods CXCL8, MMP1, BMP2 ALDH1A1 3010/4885TSHR 4201/4885SMN1; SMN2 3184/4885
US-20030044467-A1 Gel composition and methods CXCL8, MMP1, BMP2 ALDH1A1 3010/4885TSHR 4201/4885SMN1; SMN2 3184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.